Navigation Links
Safety and immunogenicity of 2 doses of the HPV-16/18 AS04 adjuvanted vaccine Cervarix
Date:3/28/2014

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

Since high coverage and compliance rates can be difficult to achieve with the current three-dose HPV vaccineregimen, several studies have looked at the possibility of reducing the number of doses. Proof-of-principle that a two-dose schedule can provide sufficient protection against cervical cancer came initially from a study performed in Costa Rica in 2011. Since then, several countries have considered switching to a two-dose schedule or have already done so. The European Commission recently granted marketing authorization for Cervarix as a two-dose schedule for girls aged 9-14 years, and outside of the EU, the Cervarix two-dose schedule is approved in more than ten countries, including Panama, Guatemala, Honduras, El Salvador, Haiti, Suriname, Chile, Guyana, Nigeria, Ghana, Pakistan, and Bangladesh.

The randomized, partially-blinded Phase I/II clinical trial evaluated the immunogenicity and safety of two doses of the licensed formulation of Cervarix (20 g each of HPV-16 and HPV-18 L1 VLPs, ,20/20') or an alternative formulation (40 g of each HPV-16 and HPV-18 VLPs; ,40/40') in different age groups, compared with the standard three-dose schedule of the licensed formulation. Healthy females (age stratified: 9-14, 15-19, 20-25 years) were randomized to receive two doses of vaccine at months 0 and 6, or three doses of the vaccine at months 0, 1, and 6.

The trial was initiated in 2007 and conducted at 21 centers in Canada and Germany. Results from 24 months of analysis were previously published in HV&I, and the current study presents results from 48 months of analysis. Since the two-dose 40/40 formulation gave no added benefit, the current study focused on data for the two-dose 20/20 formulation in girls aged 9-14 years and the standard three-dose 20/20 schedule in women aged 15-19 years.

The researchers reported that all initially seronegative subjects seroconverted for HPV-16 and HPV-18 antibodies and remained seropositive up to 48 months. The kinetics of HPV-16, -18, -31, and -45 antibody responses were similar for both groups, and the HPV-16 and -18 geometric mean antibody titers were substantially higher than titers following natural infection. The vaccine had a clinically acceptable safety profile in both groups. In summary, antibody responses to a two-dose schedule of the licensed vaccine formulation in girls aged 9-14 years appeared comparable to the standard three-dose schedule in women aged 15-19 years for up to four years after first vaccination.

These results show that a two-dose schedule should confer a similar level of protection against HPV infections and subsequent development of cervical lesions and cancer as the current three-dose schedule. A two-dose schedule obviously would be more convenient for physicians and patients, and could help reduce associated costs. The authors think that these benefits could facilitate the implementation of HPV immunization programs in low-income countries, as well as improve the relatively low vaccine coverage and series completion rates observed in some developed countries.

"Compliance has been a major challenge for HPV vaccination. These data reinforce the value of the two-dose schedule and should lead to increased utilization of this vaccine, with consequent decreases in morbidity and mortality from cervical cancer," said Dr. Ronald Ellis, Editor-in-Chief of Human Vaccines & Immunotherapeutics.


'/>"/>
Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Related medicine news :

1. Food Safety Considerations for Innovative Nutrition Solutions
2. Hospital food safety measures reduce risk of contaminated hospital food
3. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
4. Safety Management Systems Offering New Internationally Approved-courses
5. Safety Training Seminars is Proud to Announce the Opening of an American Heart Association BLS, CPR, & First-aid Certification Training School in Vallejo, Solano County
6. Rf Safe Launches Social Deal Savings On Smart Phone Radiation Safety Accessories
7. Etymotic Creates “Safety Earphones” For High Noise Environments
8. Former Nuclear-Powered Submarine Captain Advises LifeWings on Patient Safety
9. Electrical Safety Devices & Accessories Procurement Research Report Now Available from IBISWorld
10. Atlantic Neurosurgical Specialists (ANS) Offers Tips On Practicing Sports Safety During Winter Team Sports
11. InventHelp Inventors Develop Improved Safety Belt (BGF-692)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: